RU2016137122A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2016137122A3 RU2016137122A3 RU2016137122A RU2016137122A RU2016137122A3 RU 2016137122 A3 RU2016137122 A3 RU 2016137122A3 RU 2016137122 A RU2016137122 A RU 2016137122A RU 2016137122 A RU2016137122 A RU 2016137122A RU 2016137122 A3 RU2016137122 A3 RU 2016137122A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461952812P | 2014-03-13 | 2014-03-13 | |
US61/952,812 | 2014-03-13 | ||
PCT/EP2015/055119 WO2015136016A2 (en) | 2014-03-13 | 2015-03-12 | Therapeutic combinations with estrogen receptor modulators |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2016137122A RU2016137122A (ru) | 2018-04-18 |
RU2016137122A3 true RU2016137122A3 (ru) | 2018-10-19 |
Family
ID=52706145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2016137122A RU2016137122A (ru) | 2014-03-13 | 2015-03-12 | Терапевтические комбинации с модуляторами рецепторов эстрогена |
Country Status (14)
Country | Link |
---|---|
US (1) | US20150258080A1 (ru) |
EP (1) | EP3116497A2 (ru) |
JP (1) | JP2017507964A (ru) |
KR (1) | KR20160124909A (ru) |
CN (1) | CN106572990A (ru) |
AU (1) | AU2015228859A1 (ru) |
CA (1) | CA2940576A1 (ru) |
IL (1) | IL247254A0 (ru) |
MA (1) | MA39741A (ru) |
MX (1) | MX2016011636A (ru) |
RU (1) | RU2016137122A (ru) |
SG (1) | SG11201607334YA (ru) |
WO (1) | WO2015136016A2 (ru) |
ZA (1) | ZA201605712B (ru) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2915534A1 (en) | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Azetidine estrogen receptor modulators and uses thereof |
PE20160157A1 (es) | 2013-06-19 | 2016-03-18 | Seragon Pharmaceuticals Inc | Moduladores de los receptores de estrogeno y sus usos |
AU2015228860A1 (en) | 2014-03-13 | 2016-09-08 | F. Hoffmann-La Roche Ag | Methods and compositions for modulating estrogen receptor mutants |
AR101487A1 (es) | 2014-08-11 | 2016-12-21 | Hoffmann La Roche | Formas cristalinas de un modulador de receptor de estrógeno |
CR20170250A (es) | 2014-12-18 | 2017-07-19 | Hoffmann La Roche | TETRAHIDRO-PIRIDO[3,4-b]INDOLES MODULADORES DE RECEPTORES DE ESTRÓGENOS Y USOS DE LOS MISMOS |
EP3233828B1 (en) | 2014-12-18 | 2020-03-04 | F. Hoffmann-La Roche AG | Estrogen receptor modulators and uses thereof |
CA2984200C (en) | 2015-04-29 | 2024-03-19 | Radius Pharmaceuticals, Inc. | Combinations of rad1901 and a cdk 4/6 inhibitor for treating cancer |
US10053451B2 (en) | 2015-05-26 | 2018-08-21 | Genentech, Inc. | Heterocyclic estrogen receptor modulators and uses thereof |
UA120882C2 (uk) | 2015-05-29 | 2020-02-25 | ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД. | Тетразаміщені алкенові сполуки і їх застосування |
US9975856B2 (en) | 2015-10-07 | 2018-05-22 | Genentech, Inc. | Process for the preparation of (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid |
RU2747802C2 (ru) | 2015-12-09 | 2021-05-14 | Зе Боард Оф Трастис Оф Зе Юниверсити Оф Иллинойс | Бензотиофеновые селективные блокаторы эстрогеновых рецепторов |
US10519143B2 (en) | 2016-03-25 | 2019-12-31 | Luoxin Pharmaceutical (Shanghai) Co., Ltd. | Substituted-indole-compounds as estrogen receptor down-regulators |
CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
US20180002344A1 (en) | 2016-06-16 | 2018-01-04 | Genentech, Inc. | Heteroaryl estrogen receptor modulators and uses thereof |
RU2019102647A (ru) | 2016-07-01 | 2020-08-03 | Г1 Терапьютикс, Инк. | Антипролиферационные средства на основе пиримидина |
ES2898072T3 (es) * | 2016-09-27 | 2022-03-03 | Radius Pharmaceuticals Inc | Métodos para tratar el cáncer de ovario |
US20180098963A1 (en) | 2016-10-11 | 2018-04-12 | Duke University | Lasofoxifene treatment of breast cancer |
CN107973780B (zh) * | 2016-10-21 | 2020-10-09 | 四川科伦博泰生物医药股份有限公司 | 一种取代的烯烃类化合物及其制备方法和用途 |
WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
EP3544956A1 (en) * | 2016-11-24 | 2019-10-02 | Eisai R&D Management Co., Ltd. | Tetrasubstituted alkene compounds and their use |
JP6346368B1 (ja) | 2016-11-28 | 2018-06-20 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | インダゾール誘導体の塩及びその結晶 |
PL3689868T3 (pl) * | 2016-12-01 | 2024-03-11 | Arvinas Operations, Inc. | Pochodne tetrahydronaftalenu i tetrahydroizochinoliny jako degradery receptorów estrogenowych |
CA3048057A1 (en) | 2017-01-06 | 2018-07-12 | G1 Therapeutics, Inc. | Combination therapy for the treatment of cancer |
AU2018217809A1 (en) | 2017-02-10 | 2019-08-22 | G1 Therapeutics, Inc. | Benzothiophene estrogen receptor modulators |
EP4218820A3 (en) | 2017-03-16 | 2023-09-20 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of breast cancer |
CA3067873A1 (en) | 2017-06-29 | 2019-01-03 | G1 Therapeutics, Inc. | Morphic forms of g1t38 and methods of manufacture thereof |
WO2019057201A1 (zh) * | 2017-09-25 | 2019-03-28 | 罗欣生物科技(上海)有限公司 | 一种雌激素受体抑制剂的晶型及其制备方法 |
WO2019097426A1 (en) | 2017-11-16 | 2019-05-23 | Novartis Ag | Pharmaceutical combination comprising lsz102 and ribociclib |
JP2021504384A (ja) | 2017-12-01 | 2021-02-15 | ノバルティス アーゲー | Lsz102及びアルペリシブを含む医薬品の組合せ |
WO2019199891A1 (en) * | 2018-04-10 | 2019-10-17 | Duke University | Lasofoxifene treatment of breast cancer |
HRP20230859T1 (hr) | 2018-06-21 | 2023-11-10 | F. Hoffmann - La Roche Ag | Kruti oblici soli tartarata 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropil)azetidin-3-il)amino)fenil)-3-metil-1,3,4,9-tetrahidro-2hpirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol, postupak njihove proizvodnje i postupci njihove primjene u liječenju raka |
WO2020132561A1 (en) | 2018-12-20 | 2020-06-25 | C4 Therapeutics, Inc. | Targeted protein degradation |
JP2022540421A (ja) * | 2019-07-07 | 2022-09-15 | オレマ ファーマシューティカルズ インク. | エストロゲン受容体アンタゴニストのレジメン |
US11576919B2 (en) | 2019-08-12 | 2023-02-14 | Genentech, Inc. | Treatment of breast cancer using combination therapies comprising an ATP competitive AKT inhibitor, a CDK4/6 inhibitor, and fulvestrant |
CN114901277B (zh) | 2019-12-20 | 2024-05-17 | C4医药公司 | 用于egfr降解的异吲哚啉酮和吲唑化合物 |
CA3189841A1 (en) * | 2020-07-30 | 2022-02-03 | Acer Therapeutics Inc. | Nk receptor antagonists for cancer patients |
CN114748480B (zh) * | 2021-01-08 | 2023-10-20 | 轩竹生物科技股份有限公司 | 一种预防和/或治疗癌症的药物组合物 |
GB202116903D0 (en) | 2021-11-18 | 2022-01-05 | Sermonix Pharmaceuticals Inc | Lasofoxifene treatment of aromatase-resistant er+ cancer |
WO2024030968A1 (en) | 2022-08-03 | 2024-02-08 | Brystol-Myers Squibb Company | Compounds for modulating ret protein |
WO2024033513A1 (en) | 2022-08-11 | 2024-02-15 | Diaccurate | Compounds for treating cancer |
WO2024097989A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein degraders |
WO2024097980A1 (en) | 2022-11-04 | 2024-05-10 | Bristol-Myers Squibb Company | Ret-ldd protein inhibitors |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5583024A (en) | 1985-12-02 | 1996-12-10 | The Regents Of The University Of California | Recombinant expression of Coleoptera luciferase |
JPH08336393A (ja) | 1995-04-13 | 1996-12-24 | Mitsubishi Chem Corp | 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法 |
US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
DE602007007323D1 (de) | 2006-04-26 | 2010-08-05 | Hoffmann La Roche | Thienoä3,2-düpyrimidin-derivat geeignet als pi3k inhibitor |
US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
US8623604B2 (en) * | 2009-09-09 | 2014-01-07 | Quintiles Transnational Corp. | Methods for predicting responsiveness of a cancer cell to an anti-IGFR1 antibody by analysis of mutations in PIK3CA |
CN102762576B (zh) | 2009-09-28 | 2015-04-22 | 霍夫曼-拉罗奇有限公司 | 苯并氧杂氮杂*pi3k抑制剂化合物和使用方法 |
CA2800673A1 (en) * | 2010-06-10 | 2011-12-15 | Aragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
WO2013090836A1 (en) | 2011-12-14 | 2013-06-20 | Aragon Pharmaceuticals, Inc. | Fluorinated estrogen receptor modulators and uses thereof |
CA2857061A1 (en) * | 2011-12-16 | 2013-06-20 | Olema Pharmaceuticals, Inc. | Novel benzopyran compounds, compositions and uses thereof |
EP2809312A1 (en) * | 2012-01-31 | 2014-12-10 | Novartis AG | Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer |
EA201491530A1 (ru) | 2012-03-20 | 2015-07-30 | Серагон Фармасьютикалс, Инк. | Модуляторы рецепторов эстрогенов и их применение |
SG11201407537YA (en) * | 2012-06-08 | 2014-12-30 | Hoffmann La Roche | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
KR101435193B1 (ko) | 2012-08-10 | 2014-09-01 | 주식회사 일광 | 자동차용 사이드 임팩트바 제조 방법 |
CA2899969A1 (en) | 2013-03-14 | 2014-09-25 | Seragon Pharmaceuticals, Inc. | Polycyclic estrogen receptor modulators and uses thereof |
WO2014203129A1 (en) * | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinations of benzopyran compounds, compositions and uses thereof |
PE20160157A1 (es) * | 2013-06-19 | 2016-03-18 | Seragon Pharmaceuticals Inc | Moduladores de los receptores de estrogeno y sus usos |
WO2014203132A1 (en) * | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Substituted benzopyran compounds, compositions and uses thereof |
CA2915534A1 (en) | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Azetidine estrogen receptor modulators and uses thereof |
-
2015
- 2015-03-12 US US14/645,585 patent/US20150258080A1/en not_active Abandoned
- 2015-03-12 SG SG11201607334YA patent/SG11201607334YA/en unknown
- 2015-03-12 CN CN201580024933.7A patent/CN106572990A/zh active Pending
- 2015-03-12 CA CA2940576A patent/CA2940576A1/en not_active Abandoned
- 2015-03-12 KR KR1020167028316A patent/KR20160124909A/ko unknown
- 2015-03-12 MA MA039741A patent/MA39741A/fr unknown
- 2015-03-12 MX MX2016011636A patent/MX2016011636A/es unknown
- 2015-03-12 AU AU2015228859A patent/AU2015228859A1/en not_active Abandoned
- 2015-03-12 JP JP2016556835A patent/JP2017507964A/ja active Pending
- 2015-03-12 RU RU2016137122A patent/RU2016137122A/ru not_active Application Discontinuation
- 2015-03-12 EP EP15711448.9A patent/EP3116497A2/en not_active Withdrawn
- 2015-03-12 WO PCT/EP2015/055119 patent/WO2015136016A2/en active Application Filing
-
2016
- 2016-08-11 IL IL247254A patent/IL247254A0/en unknown
- 2016-08-17 ZA ZA2016/05712A patent/ZA201605712B/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2015136016A3 (en) | 2015-12-10 |
US20150258080A1 (en) | 2015-09-17 |
RU2016137122A (ru) | 2018-04-18 |
WO2015136016A2 (en) | 2015-09-17 |
SG11201607334YA (en) | 2016-10-28 |
JP2017507964A (ja) | 2017-03-23 |
ZA201605712B (en) | 2019-04-24 |
AU2015228859A1 (en) | 2016-07-07 |
MX2016011636A (es) | 2016-12-12 |
MA39741A (fr) | 2017-01-18 |
CA2940576A1 (en) | 2015-09-17 |
IL247254A0 (en) | 2016-09-29 |
CN106572990A (zh) | 2017-04-19 |
EP3116497A2 (en) | 2017-01-18 |
KR20160124909A (ko) | 2016-10-28 |
Similar Documents
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190207 |